Increasing prevalence and incidence of thyroid disease in Tayside, Scotland: The Thyroid Epidemiology, Audit and Research Study (TEARS)
Division of Medicine and Therapeutics, University of Dundee, UK. Clinical Endocrinology
(Impact Factor: 3.46).
02/2008; 68(2):311-6. DOI: 10.1111/j.1365-2265.2007.03051.x
We aimed to describe the changing incidence of thyroid disease in a population-based study in Tayside, Scotland (population 390 000) between 1994 and 2001.
A retrospective, data-linkage, population-based study measuring the incidence and prevalence of thyroid disease.
All patients with newly diagnosed, treated and stable thyroid disease in Tayside were identified by electronic linkage of six datasets, including all regional biochemistry data, hospital admissions, deaths and a thyroid follow-up register.
The overall prevalence of thyroid dysfunction has increased from 2.3% to 3.8% (1994-2001). The prevalence of ever having had hyperthyroidism increased from 0.86% to 1.26% in females and 0.17% to 0.24% in males (P < 0.0001 for both). The standardized incidence of hyperthyroidism increased from 0.68 to 0.87 per 1000 females/year, representing a 6.3% annual increase (P < 0.0001). The prevalence of primary hypothyroidism increased from 3.12% to 5.14% in females and 0.51% to 0.88% in males (P < 0.0001 for both). The standardized incidence of primary hypothyroidism did not change and varied between 3.90 and 4.89 per 1000 females/year over the 8 years. Incidence of hypothyroidism in males increased from 0.65 to 1.01 per 1000 males/year (P = 0.0017). Mean age at diagnosis of primary hypothyroidism declined in females from 1994 to 2001.
The prevalence of primary hypothyroidism and previous hyperthyroidism has increased in Tayside, Scotland. This is partly due to an increasing incidence of disease, increased ascertainment and earlier diagnosis of disease. This will result in an increased workload for endocrinologists and general practitioners.
Available from: Alexander (Ander) Thomas Cohen
- "The prevalence of DM in medical wards is 20–35% (Mazurek et al, 2010; Feldman-Billard et al, 2013). Thyroid disease is common with a prevalence of around one-third of that of diabetes (Leese et al, 2008). Gout is also a relatively common disorder (Annemans et al, 2008). "
Available from: Anselmo Papa
- "The prevalence of hypothyroidism in the general population ranges from 3.8 to 4.6% (Tunbridge et al. 1977, Vanderpump et al. 1995, Hollowell et al. 2002, Leese et al. 2008). Hypothyroidism has different etiologies and manifestations and may be subclinical or overt. "
[Show abstract] [Hide abstract]
ABSTRACT: The incidence of kidney cancer has increased worldwide in the last years. Although the most common type of kidney cancer is localized RCC, with a 5-year survival rate of 85%, about one third of patients present advanced or metastatic disease at diagnosis, with a 5-year survival rate of only 10%. Multitargeted receptor tyrosine kinase inhibitors (sunitinib and sorafenib), the anti-VEGF monoclonal antibody bevacizumab in association with interferon-alfa, the mTOR inhibitors are now approved for the treatment of mRCC. Recently the novel agents pazopanib and axitinib have also demonstrated efficacy in mRCC patients. Several recent retrospective and prospective trials have suggested that some of their adverse events, such as hypertension, hypothyroidism and HFS, may act as potential biomarkers of response and efficacy of treatment. In this review we analyzed the studies which have suggested a relationship between hypothyroidism onset and a better outcome of mRCC patients treated with tyrosine kinase inhibitors. The biological mechanisms suggesting and explaining this correlation are not well known and different speculative theories have been considered in order to investigate the clinical link between hypothyroidism occurrence and the prolonged therapy with tyrosine kinase inhibitors in solid tumors. Furthermore, the management of this unexplained side effect is very important to maximize the efficacy of therapy in mRCC patients, because there is a clear and consistent relationship between drug dose and efficacy of treatment. Certainly other studies are needed to clarify if a better outcome is associated to hypothyroidism induced to tyrosine kinase inhibitors in patients with mRCC.
Available from: Seishi Furukawa
- "Thyroid dysfunction is present in 2.3–3.8% in general , as well as during pregnancy . However, nearly 10% of abnormal thyroid function was observed according to thyroid function survey using general health checkup system for the adult in Japan . "
[Show abstract] [Hide abstract]
We conducted the study to see the incidence of thyroid dysfunction in women with obstetrical high-risk factors.
We retrospectively reviewed medical charts of high-risk pregnant women who had examination for thyroid function during pregnancy. Women were divided according to clinical presentation, symptoms of thyroid disease and those with a personal history of thyroid disease (thyroid disease, n = 32), intrauterine growth restriction (IUGR, n = 115), diabetes mellitus (diabetes, n = 115), hypertension (n = 63), intrauterine fetal death (IUFD, n = 52), and placental abruption (abruption, n = 15). The incidence of thyroid dysfunctions including hyperthyroidism or hypothyroidism was compared.
The overall prevalence of thyroid dysfunction was 24.7%. The incidence of thyroid dysfunction in each group was as follows: 31% in thyroid disease, 25% in IUGR, 30% in diabetes, 27% in hypertension, 12% in IUFD, and 7% in abruption. Except IUFD, the incidence was not statistically significant from the group of thyroid disease (thyroid disease versus IUFD, P = 0.03 by χ (2) test). Thyroid disease represented for only 10% of all thyroid dysfunctions.
Testing of women with a personal history or current symptoms of thyroid disease during pregnancy may be insufficient to detect women with thyroid dysfunction, who will become at high-risk pregnancy.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.